
SENATE COMMITTEE AMENDMENTS

2026 Regular Session

Amendments proposed by Senate Committee on Health and Welfare to Original Senate Bill
No. 43 by Senator McMath

1 AMENDMENT NO. 1

2 On page 1, line 3, after "R.S. 28:211" insert "and 212"

3 AMENDMENT NO. 2

4 On page 1, line 5, after "studies;" insert "to provide for drug development clinical trials;"

5 AMENDMENT NO. 3

6 On page 1, line 9, change "R.S. 28:211, is" to "R.S. 28:211 and 212, are"

7 AMENDMENT NO. 4

8 On page 1, line 12, change "**Section**" to "**Part**"

9 AMENDMENT NO. 5

10 On page 1, between lines 15 and 16, insert the following:

11 **"(2) "Drug developer" means a pharmaceutical company, biotechnology**
12 **company, or contract development and manufacturing organization engaged in drug**
13 **development and manufacturing.**

14 **(3) "Ibogaine" means ibogaine and ibogaine-based therapeutics, including**
15 **ibogaine analogs."**

16 AMENDMENT NO. 6

17 On page 1, line 16, change "**(2)**" to "**(4)**"

18 AMENDMENT NO. 7

19 On page 2, line 2, change "**(3)**" to "**(5)**"

20 AMENDMENT NO. 8

21 On page 2, line 10, delete "**assist**" and insert "**identify**" and after "**centers**" delete "**in**"

22 AMENDMENT NO. 9

23 On page 2, delete lines 18 and 19 and insert the following:

24 **"C. The Louisiana Department of Health shall maintain a record of all academic**
25 **health centers participating in the program.**

26 **D. Each participating academic health center shall maintain documentation"**

27 AMENDMENT NO. 10

28 On page 2, line 22, after "**application**" insert "**, expanded access program, or other**
29 **federally authorized pathway**"

30 AMENDMENT NO. 11

31 On page 3, delete lines 8 through 10

1 AMENDMENT NO. 12

2 On page 3, line 11, change "(c)" to "(b)"

3 AMENDMENT NO. 13

4 On page 3, line 13, change "(d)" to "(c)"

5 AMENDMENT NO. 14

6 On page 3, line 15, change "(e)" to "(d)"

7 AMENDMENT NO. 15

8 On page 4, line 4, change "D." to "E."

9 AMENDMENT NO. 16

10 On page 4, line 9, change "E." to "F."

11 AMENDMENT NO. 17

12 On page 4, line 16, change "F." to "G."

13 AMENDMENT NO. 18

14 On page 4, line 22, change "G." to "H."

15 AMENDMENT NO. 19

16 On page 4, after line 24, insert the following:

17 **"§212. Drug development of ibogaine treatment**

18 **A. An academic health center may enter into an agreement with a drug**
19 **developer to establish a consortium for purpose of conducting drug development**
20 **clinical trials with ibogaine and securing the United States Food and Drug**
21 **Administration's approval of ibogaine as a medication for the treatment of opioid use**
22 **disorder, co-occurring substance use disorder, and any other neurological or mental**
23 **health condition for which ibogaine demonstrates efficacy.**

24 **B. A consortium seeking to conduct an ibogaine drug development clinical trial**
25 **shall:**

26 **(1) Submit an investigational new drug application to the FDA in accordance**
27 **with 21 CFR Part 312.**

28 **(2) Seek a breakthrough therapy designation for ibogaine from the FDA under**
29 **21 U.S.C. 356.**

30 **(3) Enter into an agreement with a consortium established by the government**
31 **of another state, whether acting through an agent or joint venture, that has taken both**
32 **of the following actions:**

33 **(a) Has submitted an investigational new drug application to the FDA in**
34 **accordance with 21 CFR Part 312.**

35 **(b) Has requested a breakthrough therapy designation for ibogaine from the**
36 **FDA under 21 U.S.C. 356.**

37 **(4) Work with the FDA to coordinate the drug development trial in Louisiana**
38 **with ibogaine drug development trials that are being conducted in other states.**

39 **C.(1) Any revenue attributable to all intellectual property rights and other**
40 **commercial rights arising from drug development clinical trials conducted by a**
41 **consortium pursuant to this Section, during the period for which the trials are funded,**
42 **and any following period of commercialization shall be allocated as follows:**

43 **(a) Not less than twenty percent to the state.**

44 **(b) The remainder to the members of the consortium in the amounts specified**
45 **by written agreement of the members.**

1 **(2) Intellectual property rights and other commercial rights arising from the**
2 **drug development clinical trials conducted pursuant to this Section shall include any**
3 **of the following as related to the trials:**

4 **(a) Intellectual property, technology, and inventions.**

5 **(b) Patents, trademarks, and licenses.**

6 **(c) Proprietary and confidential information.**

7 **(d) Trade secrets, data, and databases.**

8 **(e) Tools, methods, and processes.**

9 **(f) Treatment models or techniques.**

10 **(g) Administration protocols.**

11 **(h) Works of authorship."**